Comparative Pharmacology
Head-to-head clinical analysis: KETOTIFEN FUMARATE versus X TROZINE L A.
Peer-Reviewed Evidence
Head-to-head clinical analysis: KETOTIFEN FUMARATE versus X TROZINE L A.
KETOTIFEN FUMARATE vs X-TROZINE L.A.
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Antihistamine and mast cell stabilizer; inhibits release of histamine and other mediators from mast cells; also blocks histamine H1 receptors.
X-TROZINE L.A. is a piperazine derivative that acts as a centrally acting alpha-2 adrenergic agonist, reducing sympathetic outflow from the brainstem, leading to decreased peripheral vascular resistance and lowered blood pressure.
1 mg orally twice daily; ophthalmic: 1 drop in each eye every 8-12 hours.
250 mg orally once daily. May be increased to 500 mg once daily if needed.
None Documented
None Documented
Terminal half-life 12-24 hours (mean 18 hours); requires twice-daily dosing after initial titration.
12-15 hours; prolonged in renal impairment (up to 30 hours in CrCl <30 mL/min).
Renal (50-70% as conjugates, <2% unchanged), fecal (<10%), with enterohepatic circulation.
Primarily renal (70-80% as unchanged drug), with 20-30% fecal via biliary excretion.
Category A/B
Category C
Antihistamine / Mast Cell Stabilizer
Antihistamine